Drug utilization and medication costs at the end of life

Lisa Pont, Kristian Jansen, Margrete Aase Schaufel, Dagny Faksvåg Haugen, Sabine Ruths

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

In the end stages of life, drug treatment goals shift to symptom control and quality of life and as such changes in drug utilization are expected. The aim of this paper is to review the extent to which costs are considered in drug utilization research at the end of life, with a particular focus on the outcome measures being used. This systematic review identified seven studies across varied settings studies reporting both drug utilization and medication cost outcome measures. The main factors identified that impacted medication use and cost were the time period considered and the provision of specialist palliative care services. Combining drug utilization and medication cost outcomes is critical for the allocation of healthcare resources and the development of a sound health policy.

LanguageEnglish
Pages237-243
Number of pages7
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume16
Issue number2
DOIs
Publication statusPublished - 3 Mar 2016

Fingerprint

Drug Utilization
Costs and Cost Analysis
Outcome Assessment (Health Care)
Resource Allocation
Health Policy
Palliative Care
Quality of Life
Delivery of Health Care
Research
Pharmaceutical Preparations

Keywords

  • drug utilization
  • End-of-life
  • medication costs
  • palliative care
  • systematic review

Cite this

Pont, Lisa ; Jansen, Kristian ; Schaufel, Margrete Aase ; Haugen, Dagny Faksvåg ; Ruths, Sabine. / Drug utilization and medication costs at the end of life. In: Expert Review of Pharmacoeconomics and Outcomes Research. 2016 ; Vol. 16, No. 2. pp. 237-243.
@article{bdd42fc4be854d37a20f43b59bf4e412,
title = "Drug utilization and medication costs at the end of life",
abstract = "In the end stages of life, drug treatment goals shift to symptom control and quality of life and as such changes in drug utilization are expected. The aim of this paper is to review the extent to which costs are considered in drug utilization research at the end of life, with a particular focus on the outcome measures being used. This systematic review identified seven studies across varied settings studies reporting both drug utilization and medication cost outcome measures. The main factors identified that impacted medication use and cost were the time period considered and the provision of specialist palliative care services. Combining drug utilization and medication cost outcomes is critical for the allocation of healthcare resources and the development of a sound health policy.",
keywords = "drug utilization, End-of-life, medication costs, palliative care, systematic review",
author = "Lisa Pont and Kristian Jansen and Schaufel, {Margrete Aase} and Haugen, {Dagny Faksv{\aa}g} and Sabine Ruths",
year = "2016",
month = "3",
day = "3",
doi = "10.1586/14737167.2016.1158106",
language = "English",
volume = "16",
pages = "237--243",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "2",

}

Drug utilization and medication costs at the end of life. / Pont, Lisa; Jansen, Kristian; Schaufel, Margrete Aase; Haugen, Dagny Faksvåg; Ruths, Sabine.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 16, No. 2, 03.03.2016, p. 237-243.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Drug utilization and medication costs at the end of life

AU - Pont, Lisa

AU - Jansen, Kristian

AU - Schaufel, Margrete Aase

AU - Haugen, Dagny Faksvåg

AU - Ruths, Sabine

PY - 2016/3/3

Y1 - 2016/3/3

N2 - In the end stages of life, drug treatment goals shift to symptom control and quality of life and as such changes in drug utilization are expected. The aim of this paper is to review the extent to which costs are considered in drug utilization research at the end of life, with a particular focus on the outcome measures being used. This systematic review identified seven studies across varied settings studies reporting both drug utilization and medication cost outcome measures. The main factors identified that impacted medication use and cost were the time period considered and the provision of specialist palliative care services. Combining drug utilization and medication cost outcomes is critical for the allocation of healthcare resources and the development of a sound health policy.

AB - In the end stages of life, drug treatment goals shift to symptom control and quality of life and as such changes in drug utilization are expected. The aim of this paper is to review the extent to which costs are considered in drug utilization research at the end of life, with a particular focus on the outcome measures being used. This systematic review identified seven studies across varied settings studies reporting both drug utilization and medication cost outcome measures. The main factors identified that impacted medication use and cost were the time period considered and the provision of specialist palliative care services. Combining drug utilization and medication cost outcomes is critical for the allocation of healthcare resources and the development of a sound health policy.

KW - drug utilization

KW - End-of-life

KW - medication costs

KW - palliative care

KW - systematic review

UR - http://www.scopus.com/inward/record.url?scp=84961895908&partnerID=8YFLogxK

U2 - 10.1586/14737167.2016.1158106

DO - 10.1586/14737167.2016.1158106

M3 - Review article

VL - 16

SP - 237

EP - 243

JO - Expert Review of Pharmacoeconomics and Outcomes Research

T2 - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 2

ER -